SAB Biotherapeutics, Inc. (SABS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SAB Biotherapeutics, Inc. (SABS) trades at $3.78 with AI Score 49/100 (Grade C). SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of human antibody immunotherapies. Market cap: $344M, Sector: Healthcare.
Price as of Aug 22, 2026 · Last analyzed: May 10, 2026SABS stock analysis for 2026: Analysts have set a consensus price target of $7.00 for SAB Biotherapeutics, Inc., suggesting 85.2% upside from the current price of $3.78. The AI MoonshotScore is 49/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
SABS: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
SAB Biotherapeutics, Inc. (SABS) Healthcare & Pipeline Overview
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging its DiversitAb platform to develop fully human polyclonal antibody immunotherapies. Targeting infectious diseases like COVID-19 and influenza, as well as autoimmune disorders and cancer, SAB Biotherapeutics aims to provide novel treatments without relying on human donors, positioning itself in the competitive biotechnology landscape.
What Is the Investment Thesis for SABS?
SAB Biotherapeutics presents a notable research candidate within the biotechnology sector, driven by its innovative DiversitAb platform for producing fully human polyclonal antibodies. The Phase III clinical trial of SAB-185 for COVID-19 represents a near-term catalyst. Success in this trial could lead to regulatory approval and significant revenue generation. Further value drivers include the advancement of SAB-176 for influenza and SAB-142 for autoimmune diseases. However, the company faces risks inherent in clinical-stage drug development, including potential trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market cap of $344M and a P/E ratio of 5.5, SAB Biotherapeutics' valuation reflects both its potential and the associated risks. Successful execution of its clinical programs and strategic partnerships will be critical for realizing long-term value.
Based on FMP financials and quantitative analysis
SABS Key Highlights
SAB-185 is in Phase III clinical trials for the treatment of COVID-19, representing a near-term potential revenue catalyst.
- DiversitAb platform offers a unique approach to producing fully human polyclonal antibodies without the need for human donors.
- SAB-176 is in development for the treatment or prevention of severe influenza, addressing a significant market need.
- Pre-clinical program SAB-142 targets autoimmune diseases like type 1 diabetes and organ transplant rejection, expanding the therapeutic pipeline.
- The company's market capitalization is $0.04 billion with a P/E ratio of 5.5, reflecting its growth potential and associated risks.
Who Are SABS's Competitors?
SABS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NAGE Niagen Bioscience Inc | $3.21 | +1.90% | $256M | 74 |
| QTTB Q32 Bio Inc. | $15.97 | +0.69% | $475M | 83 |
| CGEN Compugen Ltd. | $2.62 | -1.32% | $247M | 76 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.81 | +0.42% | $197M | 77 |
| MDXG MiMedx Group, Inc. | $4.33 | +0.70% | $631M | 90 |
| CRMD CorMedix Inc. | $8.20 | -0.36% | $643M | 95 |
| ZVRA Zevra Therapeutics, Inc. | $11.87 | -0.17% | $702M | 93 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SABS's Key Strengths?
Innovative DiversitAb platform for antibody production.
- Fully human polyclonal antibodies offer potential advantages over monoclonal antibodies.
- Lead product candidate SAB-185 in Phase III clinical trials.
- Experienced management team with expertise in antibody development.
What Are SABS's Weaknesses?
Clinical-stage company with no currently approved products.
- Reliance on the success of clinical trials for future revenue.
- Limited financial resources compared to larger pharmaceutical companies.
- Potential for competition from established antibody therapeutics.
What Could Drive SABS Stock Higher?
SABS catalyst: Data readout from the Phase III clinical trial of SAB-185 for COVID-19 in late 2026.
- Initiation of Phase II clinical trials for SAB-176 for influenza in 2027.
- Potential regulatory submissions for SAB-185 based on clinical trial results.
- Expansion of the DiversitAb platform to develop antibodies for new disease targets.
- Strategic partnerships and collaborations with pharmaceutical companies.
What Are the Key Risks for SABS?
Negative return on equity (-6.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays for SAB-185 and other product candidates.
- Regulatory setbacks and challenges in obtaining marketing approval.
- Competition from established pharmaceutical companies and antibody therapeutics.
- Dependence on funding and capital markets to support research and development.
- Intellectual property challenges and patent disputes.
What Are the Growth Opportunities for SABS?
- Growth opportunity 1: Successful completion of the Phase III clinical trial for SAB-185 in COVID-19 could lead to Emergency Use Authorization (EUA) or full regulatory approval, potentially generating significant revenue. The global market for COVID-19 therapeutics remains substantial, with ongoing needs for effective treatments against emerging variants. Securing government contracts or partnerships with pharmaceutical companies could accelerate market penetration and commercial success. Timeline: Anticipated data readout and potential regulatory submissions in late 2026.
- Growth opportunity 2: Advancing SAB-176 for influenza represents a significant growth opportunity, addressing a large and recurring market. Positive clinical trial results and strategic partnerships could position SAB-176 as a leading influenza therapeutic. Timeline: Phase II clinical trials anticipated to commence in 2027.
- Growth opportunity 3: Expansion of the pre-clinical program SAB-142 into clinical trials for type 1 diabetes and organ transplant rejection offers long-term growth potential. The market for autoimmune disease therapies is substantial and growing, driven by increasing prevalence and unmet medical needs. Successful development of SAB-142 could provide a novel treatment option for these conditions. Timeline: Phase I clinical trials anticipated to commence in 2028.
- Growth opportunity 4: Strategic partnerships with pharmaceutical companies or research institutions could accelerate the development and commercialization of SAB Biotherapeutics' pipeline. Collaborations could provide access to funding, expertise, and distribution channels, enhancing the company's competitive position. Identifying partners with complementary capabilities and shared strategic goals is crucial for maximizing the benefits of such alliances. Ongoing:
- Growth opportunity 5: Expanding the DiversitAb platform to develop antibodies for other infectious diseases and therapeutic areas represents a long-term growth opportunity. The platform's versatility allows for the rapid generation of fully human polyclonal antibodies against a wide range of targets. Identifying new disease targets and developing novel antibody therapeutics could drive future revenue growth and market expansion. Ongoing:
What Threats Does SABS Face?
- Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies.
- Changes in government regulations and healthcare policies.
- Economic downturn and reduced healthcare spending.
What Are SABS's Competitive Advantages?
- DiversitAb platform provides a unique and scalable source of fully human polyclonal antibodies.
- Intellectual property protection for the DiversitAb platform and antibody therapeutics.
- Established expertise in genetic engineering and antibody science.
- Potential for lower manufacturing costs compared to traditional antibody production methods.
What Does SABS Do?
Founded in 2014 and based in Sioux Falls, South Dakota, SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies. The company's core technology, the DiversitAb platform, utilizes advanced genetic engineering and antibody science to create transchromosomic bovine herds. These herds are engineered to produce fully human polyclonal antibodies targeted at a range of diseases. This approach eliminates the need for human donors, offering a scalable and consistent source of human antibodies. SAB Biotherapeutics' lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic currently in Phase III clinical trials for the treatment of COVID-19. Another key candidate is SAB-176, a fully-human polyclonal antibody therapeutic in development for the treatment or prevention of severe influenza. The company also has pre-clinical programs, including SAB-142, targeting autoimmune diseases such as type 1 diabetes and organ transplant induction/rejection. The company's focus on polyclonal antibodies provides a broader range of binding sites compared to monoclonal antibodies, potentially offering improved efficacy against evolving pathogens and complex diseases. SAB Biotherapeutics is dedicated to addressing unmet medical needs through its novel antibody platform.
What Products and Services Does SABS Offer?
- Develop immunotherapies based on fully human antibodies.
- Utilize genetically engineered bovine herds to produce human antibodies.
- Target infectious diseases, including COVID-19 and influenza.
- Develop treatments for immune and autoimmune disorders, such as type 1 diabetes.
- Create therapies for organ transplantation.
- Develop treatments for cancer.
- Use the DiversitAb immunotherapy platform to produce polyclonal antibodies.
How Does SABS Make Money?
- Develop and commercialize antibody-based therapeutics.
- Generate revenue through partnerships and collaborations.
- Out-licensing of technology and intellectual property.
- Government grants and funding for research and development.
What Industry Does SABS Operate In?
SAB Biotherapeutics operates within the competitive biotechnology industry, which is characterized by high R&D spending, regulatory scrutiny, and the potential for significant returns on successful drug development. The market for antibody therapeutics is experiencing substantial growth, driven by advancements in genetic engineering and immunology. SAB Biotherapeutics' DiversitAb platform positions it to capitalize on this trend by offering a novel approach to antibody production. Competition includes established pharmaceutical companies and other biotechnology firms developing antibody-based therapies.
Who Are SABS's Key Customers?
- Patients suffering from infectious diseases like COVID-19 and influenza.
- Individuals with autoimmune disorders, such as type 1 diabetes.
- Organ transplant recipients.
- Cancer patients.
How SAB Biotherapeutics, Inc. Is Valued
SAB Biotherapeutics, Inc. carries a market capitalization of $344M, placing it in the small-cap category. Relative to its peer group, SABS's quantitative score of 49/100 is below the peer average of 76/100.
Company Profile
SAB Biotherapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Miami Beach, US. The company is led by CEO Samuel J. Reich. SABS has traded publicly since 2021.
Key Financial Metrics
Return on equity for SAB Biotherapeutics, Inc. stands at -6.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.22 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
SAB Biotherapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 8.04 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project SAB Biotherapeutics, Inc. revenue of about $333K for fiscal 2026, with EPS near $-1.20. The estimate reflects 5 contributing analysts.
SABS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative nature of SAB Biotherapeutics' therapeutic approaches.
- The increasing focus on biotechnology in the market has led to heightened interest in companies like SAB, which are pioneering new treatments.
- Recent partnerships and collaborations have sparked optimism about the company's growth trajectory and ability to bring products to market.
Bear Case
- Concerns about the regulatory environment for biopharmaceuticals may weigh on investor sentiment, creating uncertainty around approval timelines.
- Some community members express skepticism regarding the scalability of SAB's technology, fearing it may not meet market demands.
- Recent market volatility has led to a cautious approach among investors, with many preferring to wait for more stability before committing to biotech stocks.
- Competitive pressures from larger biotech firms could overshadow SAB's innovations, leading to fears of market share erosion.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SABS Latest News
No recent news available for SABS.
SABS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SABS.
Price Targets
Consensus target: $7.00
SABS MoonshotScore
What does this score mean?
The MoonshotScore rates SABS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Samuel J. Reich
CEO
Samuel J. Reich serves as the CEO of SAB Biotherapeutics, bringing extensive experience in the biotechnology and pharmaceutical industries. His background includes leadership roles in various companies focused on drug development and commercialization. Reich's expertise spans strategic planning, business development, and financial management. He has a proven track record of driving innovation and building successful biotechnology companies.
Track Record: Under Samuel J. Reich's leadership, SAB Biotherapeutics has advanced its DiversitAb platform and progressed its lead product candidates through clinical development. Key achievements include the initiation of the Phase III clinical trial for SAB-185 and the expansion of the company's pipeline into autoimmune diseases. Reich has also secured strategic partnerships and funding to support the company's growth.
SAB Biotherapeutics, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for SABS?
SABS holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of human antibody immunotherapies. Their DiversitAb platform utilizes genetically engineered …
What does SAB Biotherapeutics, Inc. do?
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that develops immunotherapies based on fully human polyclonal antibodies. The company's proprietary DiversitAb platform utilizes genetically engineered bovine herds to produce these antibodies, which are targeted at infectious diseases, autoimmune disorders, and cancer. SAB Biotherapeutics aims to provide novel treatments without relying on human donors, offering a scalable and consistent source of human antibodies for various therapeutic applications.
What do analysts say about SABS stock?
Analyst coverage of SAB Biotherapeutics, Inc. is limited, reflecting its clinical-stage status and smaller market capitalization. Key valuation metrics include its market cap of $344M and P/E ratio of 5.5. Growth considerations center on the successful completion of clinical trials for its lead product candidates, particularly SAB-185 for COVID-19.
What are the main risks for SABS?
The main risks for SAB Biotherapeutics, Inc. include the inherent uncertainties of clinical-stage drug development, such as potential trial failures or delays. Regulatory setbacks and competition from established pharmaceutical companies also pose significant challenges. The company's reliance on funding and capital markets to support its research and development activities represents another key risk.
What are the key factors to evaluate for SABS?
SAB Biotherapeutics, Inc. (SABS) holds an AI score of 49/100 (low). P/E: 5.5x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does SABS data refresh on this page?
SABS's price was last updated on Aug 22, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SABS's recent stock price performance?
SAB Biotherapeutics, Inc. (SABS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative DiversitAb platform for antibody production. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SABS overvalued or undervalued right now?
SAB Biotherapeutics, Inc. (SABS) trades at 5.5x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SABS before investing?
Before investing in SAB Biotherapeutics, Inc. (SABS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of the latest available reporting period.